Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale
暂无分享,去创建一个
[1] K. O'Byrne,et al. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance , 2020, Frontiers in Cell and Developmental Biology.
[2] D. Bushnell,et al. Overview and Current Status of Peptide Receptor Radionuclide Therapy. , 2020, Surgical oncology clinics of North America.
[3] J. Beauregard,et al. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[4] P. Bernhardt,et al. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases , 2019, The Journal of Nuclear Medicine.
[5] R. Shah,et al. Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor , 2018, Oncotarget.
[6] H. Lundqvist,et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[7] M Båth,et al. Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved 177Lu images , 2018, EJNMMI Physics.
[8] P. Bernhardt,et al. Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in 177Lu-DOTATATE Treatments. , 2017, Cancer biotherapy & radiopharmaceuticals.
[9] Val Gebski,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[10] J. Strosberg,et al. Radionuclide Therapy for Neuroendocrine Tumors , 2017, Current Oncology Reports.
[11] Ola Nilsson,et al. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors , 2016, The Journal of Nuclear Medicine.
[12] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[13] P. Bernhardt,et al. A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity , 2016, EJNMMI Physics.
[14] Iain J Hyndman,et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma , 2016, BMC Cancer.
[15] C. V. van Eijck,et al. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib , 2016, Theranostics.
[16] G. ClaringboldPhillip,et al. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study , 2015 .
[17] J. Turner,et al. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy , 2015, Neuroendocrinology.
[18] Eva Forssell-Aronsson,et al. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[19] J. Turner,et al. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. , 2012, Cancer biotherapy & radiopharmaceuticals.
[20] J. Turner,et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[21] E. Krenning,et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[22] Eva Forssell-Aronsson,et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. , 2001, International journal of radiation oncology, biology, physics.
[23] R. Herrmann,et al. Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.
[24] M. Williams,et al. Basic clinical radiobiology , 1994, British Journal of Cancer.